Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate

  • Evotec SE's EVO subsidiary, Just - Evotec Biologics Inc, has expanded a multi-year partnership with Alpine Immune Sciences Inc ALPN for ALPN-303 for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases. 
  • The contract is a continuation of their first-in-human program initiated in 2020, in which Just - Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine's ongoing Phase 1 study and anticipated Phase 2 studies of ALPN-303.
  • Related: Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies.
  • Under the expanded contract, Just - Evotec Biologics will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303. 
  • Commercial process development activities will be performed at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington.
  • Price Action: EVO shares are down 12.7% at $12.33 during the premarket session on the last check Wednesday. ALPN stock closed at $8.49 on Tuesday.
Posted In: BiotechNewsHealth CareContractsPre-Market OutlookMoversTrading IdeasGeneralBriefswhy it's moving